No named veterinary development called "Cat Heart" was documented for September 2026. The month's closest new evidence concerns wearable heart-rate monitoring in cats, not a new disease, diagnosis, or treatment. For owners, the key message is cautious progress. Consumer monitoring may eventually help, but echocardiography remains central to diagnosis, and prescription treatment still requires veterinary screening.
Table of Contents
- What did the September wearable study find?
- Can connected devices detect feline heart disease?
- How is hypertrophic cardiomyopathy confirmed?
- What treatment option should owners know about?
What did the September wearable study find?
A September 2026 study tested the Owlet Smart Sock on 20 healthy cats while they were anesthetized. Across 307 paired readings, its heart-rate measurements closely matched a veterinary monitor, with a correlation of 0.995, according to the Veterinary Medicine and Science study. That result shows the device measured heart rate accurately under those specific conditions.
It does not prove that the sock works reliably on awake cats moving around at home. The study also did not establish its accuracy in cats with heart disease. Owners should therefore view it as an early monitoring result, not validation of a home diagnostic tool.
Can connected devices detect feline heart disease?
Not reliably enough to replace a veterinarian. In an NC State study involving 51 cats, one AI-enabled digital stethoscope detected only two of 22 murmurs identified by clinicians—a sensitivity of 9.1%, according to the university's report on the JAVMA study. A reassuring device reading could therefore create false confidence.
The finding applies to the tested stethoscope and should not automatically be extended to every digital device. Traditional examination also has limits. A murmur may occur without heart disease, while a cat with heart disease may have no murmur at all.
How is hypertrophic cardiomyopathy confirmed?
Hypertrophic cardiomyopathy, or HCM, is a condition in which the wall of the heart's left ventricle becomes abnormally thick. It may remain symptom-free before progressing to congestive heart failure, an artery-blocking blood clot, or sudden death. The University of Illinois says echocardiography—an ultrasound examination of the heart—is the diagnostic gold standard.
Veterinarians must also rule out high blood pressure and an overactive thyroid before confirming HCM, as explained in the university's feline HCM guidance. This distinction matters when a wearable reports an unusual heart rate or a clinician hears a murmur. Those findings may justify further evaluation, but neither establishes HCM by itself.
What treatment option should owners know about?
The FDA conditionally approved Felycin-CA1, or sirolimus, in 2025 as the first approved product for cats with HCM. Its specific purpose is managing ventricular thickening in cats with subclinical HCM, meaning the disease is present before clinical signs develop. The target dose is 0.3 milligrams per kilogram by mouth once weekly.
However, the medication is prescription-only and should not be used in cats with pre-existing liver disease or diabetes mellitus, according to the FDA approval notice. Owners considering treatment should expect three safeguards: Conditional approval is not the same as full approval. At this stage, the FDA requires a reasonable expectation that the drug is effective; full approval requires substantial evidence of effectiveness.
- Confirmation of subclinical HCM rather than treatment based only on a murmur or device reading.
- Screening for conditions that could change the diagnosis or make the drug unsuitable.
- A veterinarian-directed prescription and dosing plan.